Latest news with #PremierInc
Yahoo
4 days ago
- Business
- Yahoo
Fresenius Kabi Receives 2025 Premier Supplier Legacy Award
A Five-Time Winner, Fresenius Kabi is Cited for Operational Excellence LAKE ZURICH, Ill., July 17, 2025--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has received the 2025 Supplier Legacy Award from Premier, Inc., a leading technology-driven healthcare performance improvement company. This marks the fifth time since 2015 Premier has recognized Fresenius Kabi USA with this award for operational excellence. Fresenius Kabi was recognized for its long-standing support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and a commitment to lower costs. Supplier Legacy Award winners are selected by Premier member committees and have a tenure of more than three years as a Premier contracted supplier. "This award recognizes the commitment to service, innovation and collaboration by thousands of Fresenius Kabi employees from across our company," said Arun Verma, President, Fresenius Kabi Region U.S. and Member of the Executive Leadership Team, Fresenius Kabi AG. "It's especially gratifying to receive this award from a customer whose members make up more than 4,350 U.S. hospitals and health systems." "Fresenius Kabi supports Premier members by offering products and services that help improve costs, quality and operations – and deliver overall value," said Bruce Radcliff, Senior Vice President of Supply Chain at Premier. "We're honored to recognize Fresenius Kabi as a Supplier Legacy Award recipient." The Supplier Legacy Award recipients were honored during Premier's annual Breakthroughs Conference & Exhibition (July 15-17, 2025). Premier has awarded Fresenius Kabi its Supplier Legacy Award in 2015, 2017, 2018, 2021, and now in 2025. In 2024, Premier also awarded Fresenius Kabi its Trailblazer Award, one of Premier's highest honors, recognizing a national Premier-contracted supplier that delivers innovative and scalable methods and technologies to accelerate clinical evidence into real-world practice. About Fresenius Kabi As a global health care company, Fresenius Kabi is Committed to Life. The company's products, technologies, and services are used for the therapy and care of patients with critical and chronic conditions. With more than 41,000 employees and present in more than 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients' nutritional status – notably as the only corporation offering both product groups. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is a global leader in supplying blood collection bags and devices, supporting blood banks and health care facilities worldwide. The company's I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to health care and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. In line with the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of health care. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing health care solutions on a global scale. For more information, please visit To learn about U.S. career opportunities at Fresenius Kabi, visit us at and follow us on LinkedIn and Facebook. View source version on Contacts Media contact Matt Kuhn (847) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Fresenius Kabi Receives 2025 Premier Supplier Legacy Award
A Five-Time Winner, Fresenius Kabi is Cited for Operational Excellence LAKE ZURICH, Ill., July 17, 2025--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has received the 2025 Supplier Legacy Award from Premier, Inc., a leading technology-driven healthcare performance improvement company. This marks the fifth time since 2015 Premier has recognized Fresenius Kabi USA with this award for operational excellence. Fresenius Kabi was recognized for its long-standing support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and a commitment to lower costs. Supplier Legacy Award winners are selected by Premier member committees and have a tenure of more than three years as a Premier contracted supplier. "This award recognizes the commitment to service, innovation and collaboration by thousands of Fresenius Kabi employees from across our company," said Arun Verma, President, Fresenius Kabi Region U.S. and Member of the Executive Leadership Team, Fresenius Kabi AG. "It's especially gratifying to receive this award from a customer whose members make up more than 4,350 U.S. hospitals and health systems." "Fresenius Kabi supports Premier members by offering products and services that help improve costs, quality and operations – and deliver overall value," said Bruce Radcliff, Senior Vice President of Supply Chain at Premier. "We're honored to recognize Fresenius Kabi as a Supplier Legacy Award recipient." The Supplier Legacy Award recipients were honored during Premier's annual Breakthroughs Conference & Exhibition (July 15-17, 2025). Premier has awarded Fresenius Kabi its Supplier Legacy Award in 2015, 2017, 2018, 2021, and now in 2025. In 2024, Premier also awarded Fresenius Kabi its Trailblazer Award, one of Premier's highest honors, recognizing a national Premier-contracted supplier that delivers innovative and scalable methods and technologies to accelerate clinical evidence into real-world practice. About Fresenius Kabi As a global health care company, Fresenius Kabi is Committed to Life. The company's products, technologies, and services are used for the therapy and care of patients with critical and chronic conditions. With more than 41,000 employees and present in more than 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients' nutritional status – notably as the only corporation offering both product groups. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is a global leader in supplying blood collection bags and devices, supporting blood banks and health care facilities worldwide. The company's I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to health care and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. In line with the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of health care. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing health care solutions on a global scale. For more information, please visit To learn about U.S. career opportunities at Fresenius Kabi, visit us at and follow us on LinkedIn and Facebook. View source version on Contacts Media contact Matt Kuhn (847)
Yahoo
4 days ago
- Business
- Yahoo
HemoSonics Wins 2025 Supplier Horizon Award from Premier, Inc.
One of 13 companies to receive Premier, Inc.'s Supplier Horizon Award for excellence in improving healthcare performance, HemoSonics' Quantra Hemostasis System provides comprehensive hemostasis analysis in less than 15 minutes DURHAM, N.C., July 17, 2025--(BUSINESS WIRE)--HemoSonics LLC, a medical device company focused on acute bleeding management, today announced it has won the 2025 Supplier Horizon Award from Premier, Inc., a leading technology-driven healthcare performance improvement company. HemoSonics was honored for its Quantra Hemostasis System, an advanced viscoelastic testing device that accelerates decision-making, enhances patient outcomes and reduces healthcare costs by delivering rapid, actionable coagulation assessments in near real-time. One of 13 suppliers to receive the award this year, HemoSonics was recognized for its support of Premier members through exceptional local customer service and engagement, as well as value creation through clinical excellence and a commitment to lower costs. Supplier Horizon Award winners are selected by Premier member committees and have a tenure of less than three years as a Premier contracted supplier. HemoSonics' Quantra Hemostasis System comprises the Quantra Hemostasis Analyzer with QPlus and QStat Cartridges. The Quantra System utilizes innovative SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary ultrasound technology that measures the coagulation properties of a whole blood sample, providing comprehensive coagulation analysis in under 15 minutes. Doctors receive test results quickly during critical and complex surgeries, enabling timely, patient-centered decisions about bleeding management, which improves care and optimizes the use of blood products. "Our mission is to ensure that our clinician partners receive accurate test results quickly during critical, complex surgeries that allow them to make timely patient-centered clinical decisions. By doing so, patients can receive the care that they need at the moment that they need it. We will continue to work tirelessly to ensure that our customers and partners are supported, as we partner with hospitals to deliver better patient outcomes, all while lowering the cost of care," said HemoSonics President and CEO Bob Roda. "We are humbled and proud to receive the Supplier Horizon Award from Premier, Inc." HemoSonics' Quantra System is FDA-cleared for use in cardiovascular and major orthopedic surgery, trauma, and liver transplantation. It requires minimal resources to maintain, is easy to operate and interpret results, and enables hospitals to standardize a clinically and operationally efficient viscoelastic testing program. According to a 2023 Journal of Cardiothoracic Surgery study, Quantra reduced blood component use between 10% and >90%. In addition, the cost of blood products decreased by 41%. "HemoSonics supports Premier members by offering products and services that help improve costs, quality and operations – and deliver overall value," said Bruce Radcliff, Senior Vice President of Supply Chain at Premier. "We're honored to recognize HemoSonics as a Supplier Horizon Award recipient." The Supplier Horizon Award recipients were honored during Premier's annual Breakthroughs Conference & Exhibition, July 15-17, 2025. About HemoSonics HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics' flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. The Quantra System's ease of use and fast interpretation of results enable simple, more efficient point-of-care and laboratory bleeding management. Based in Durham, North Carolina, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to exploring thrombosis and hemostasis. Follow HemoSonics on LinkedIn or visit to learn more. View source version on Contacts Media Contacts: Mindy M. HullMercury Global Partners for HemoSonics+1 415 889 9977 (San Francisco)hemosonics@ Michael Held-HernandezMercury Global Partners for HemoSonics+1 480 306 1154 (Washington D.C.)hemosonics@
